Apex Lifestyle Medicine
Apex Lifestyle Medicine · Jackson Belden, OH 44718
5.0· 5 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
Apex Lifestyle Medicine is a lifestyle and wellness medicine practice in Jackson Belden, Ohio, whose website lists Dr. James Franz, DO. The site describes a collaborative, personalized and holistic approach aimed at treating underlying causes rather than only managing symptoms, and lists weight-loss, hormone and aesthetic services. Its weight-loss program is described as not a quick fix, favoring slow and steady progress. On Google it has a 5.0-star rating across 5 reviews, beginning in 2024, 2 of them in the past year; one review mentions a caring manner.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | Yes |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-07-21. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 5 Google reviews. Of the 5 reviews we analyzed, 5 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
Most recent Google reviews
Delana V.★★★★★2026-07-21Great service, kind people, they listen.
Tiffany P.★★★★★2025-04-21Everyone is always so kind and helpful.
Corey M.★★★★★2024-07-27Dr. Blood is an amazing chiropractor!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs